MLTX Prakiraan wutah bathi kanggo taun ngarep moonlaketx.com

Lambang korporat lan logo MoonLake (MLTX)

The outcomes of the final sonelokimab tests remain a critical factor for MoonLake Immunotherapeutics (MLTX). The estimated growth in net earnings per share for the coming year reflects market expectations, where the level of 0.50 is the current figure. The company's potential is based on patents for unique nanobodies designed to combat inflammation. Commercial success relies on the sales of innovative drugs to patients with autoimmune skin and joint pathologies.

MoonLake Pharma (MLTX): Prakiraan wutah bathi resik saben saham ing taun ngarep saka 28.04.2023 nganti 17.11.2026

MLTX (MoonLake Immunotherapeutics AG): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:MLTX, moonlaketx.com
Produk dadi MoonLake

To find a balance between asset value and business quality, it is essential to track the trajectory of analytical model revisions, which measures the risk of overvaluation through the dynamics of expected earnings. In the case of MoonLake Immunotherapeutics (MLTX), the shift in analyst estimates for EPS growth reflects market confidence in the commercial success of Sonelokimab and the efficacy of its unique nanobodies in clinical trials.

Analisis perusahaan pesaing

ASND (Ascendis) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Pharmaceuticals|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (Rhythm Pharma)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep akerotx.com AKRO|Metsera Therapeutics (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|CRNX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|NAMS: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|SLNO: Prakiraan wutah bathi kanggo taun ngarep|FOLD - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep 89bio Pharma|Agios Corp (AGIO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep structuretx.com (GPCR)|Prakiraan wutah bathi saben saham kanggo taun ngarep mimedx.com MDXG|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|MBX: Prakiraan wutah bathi saben saham kanggo taun ngarep|Altimmune Corp - Proyeksi tambahing bathi saben saham ing taun ngarep|Aardvark Therapeutics Inc (AARD) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi saben saham kanggo taun ngarep Biomea Fusion (BMEA)|Prakiraan wutah bathi kanggo taun ngarep QNCX|Proyeksi tambahing bathi saben saham ing taun ngarep GUTS|Prakiraan wutah bathi kanggo taun ngarep VTVT (vTv Therapeutics Inc.)|Dinamika bathi saben saham sing diarepake ing taun ngarep ATPC|Pluristem Therapeutics - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep synlogictx.com SYBX|LPCN: Prakiraan wutah bathi kanggo taun ngarep|Matinas BioPharma Holdings, Inc. - Dinamika bathi saben saham sing diarepake ing taun ngarep|SPRB (Spruce Biosciences Inc.) - Prakiraan wutah bathi kanggo taun ngarep|galecto.com (GLTO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep organovo.com ONVO|Radius Health (RDUS) - Prakiraan wutah bathi resik saben saham ing taun ngarep